James Fettiplace

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus

Daniel J. Wallace, Ellen M. Ginzler, Joan T. Merrill et al. · Arthritis & Rheumatology · 2019 · 107 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

Ian N Bruce, Murray B. Urowitz, Ronald van Vollenhoven et al. · Lupus · 2016 · 104 citations · Full text

Medicine, Immunology, Internal Medicine +15

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus

Richard Furie, Daniel J. Wallace, Cynthia Aranow et al. · Arthritis & Rheumatology · 2018 · 96 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension

Ronald van Vollenhoven, Sandra Navarra, Roger A. Levy et al. · Lara D. Veeken · 2019 · 86 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus

Winn Chatham, Anurekha Chadha, James Fettiplace et al. · Lupus · 2017 · 49 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14